Belite Bio (BLTE) EBITDA (2022 - 2026)

Belite Bio (BLTE) has reported EBITDA for 5 consecutive years, with -$26.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 88.79% year-over-year to -$26.9 million; the TTM figure through Mar 2026 stood at -$63.3 billion (down 122.12% YoY), while the FY2025 annual figure was -$77.5 million, down 112.7% from the prior year.
• EBITDA came in at -$26.9 million for Q1 2026 at Belite Bio, up from -$25.4 billion in the prior quarter.
• The five-year high for EBITDA was -$6.7 million in Q4 2022, with the low at -$25.4 billion in Q4 2025.
• Average EBITDA over 5 years is -$7.4 billion, with a median of -$6.9 billion recorded in 2023.
• Across the five-year window, EBITDA tumbled 150949.87% in 2024 and soared 99.82% in 2025, its largest moves.
• Year by year, EBITDA stood at -$6.7 million in 2022, then dropped by 3.03% to -$6.9 million in 2023, then sank by 150949.87% to -$10.4 billion in 2024, then tumbled by 145.47% to -$25.4 billion in 2025, then surged by 99.89% to -$26.9 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$26.9 million, -$25.4 billion, and -$21.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.